Vitamin D metabolism in mammary gland and breast cancer

@article{Welsh2011VitaminDM,
  title={Vitamin D metabolism in mammary gland and breast cancer},
  author={JoEllen Welsh},
  journal={Molecular and Cellular Endocrinology},
  year={2011},
  volume={347},
  pages={55-60}
}
  • J. Welsh
  • Published 5 December 2011
  • Biology
  • Molecular and Cellular Endocrinology

Figures from this paper

Vitamin D receptor (VDR) and metabolizing enzymes CYP27B1 and CYP24A1 in breast cancer.

The expression and molecular defects of VDR, CYP27B1 and CYP24A1 that perturb physiologic function, the implications for breast cancer progression and therapeutic opportunities are discussed in this paper.

Vitamin D and breast cancer: emerging concepts.

Dysregulation of vitamin D3 synthesis leads to enhanced cholangiocarcinoma growth.

  • Lindsey KennedyK. Baker H. Francis
  • Medicine, Biology
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2013

Vitamin D: Metabolism, molecular mechanisms, and mutations to malignancies

Vitamin D modulation of the cell cycle, DNA repair and apoptosis via its receptors (VDRs) may have a suppressive effect on skin cancer as some studies suggest.

Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements.

The suppression of ER expression and estrogen-mediated signaling by calcitriol in BCa cells suggests that vitamin D may be useful in the treatment of ER+ BCa and contains two negative VDREs that act in concert to bind to the VDR.

Vitamin D3-dependent VDR signaling delays ron-mediated breast tumorigenesis through suppression of β-catenin activity

Collectively, these studies delineate a protective role for VDR signaling in Ron-induced mammary tumorigenesis through disruption of β-catenin activation.
...

References

SHOWING 1-10 OF 46 REFERENCES

Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway

The hypothesis that cancer cells would exhibit reduced sensitivity to vitamin D mediated negative growth regulation and the results provide evidence that disruption of the vitamin D signaling pathway occurs early in the cancer development process.

Genistein and 17beta-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells.

Results indicate a potential, new approach for cancer prevention by counteraction of the 1,25-D-driven negative feedback, i.e., down-regulation of CYP27B1 and up-regulationOf CYP24, which prevents its own local accumulation, however, mammary cells may be more susceptible to this than colonocytes.

Vitamin D receptors in breast cancer cells

It can be stated that VDR expression is lost with de-differentiation and that receptor is essential for the antiproliferative response to 1,25-(OH)2-vitamin D3.

Genistein and 17β-estradiol, but not equol, regulate vitamin D synthesis in human colon and breast cancer cells

Results indicate a potential, new approach for cancer prevention by counteraction of the 1,25-D-driven negative feedback, i.e., down-regulation of CYP27B1 and up-regulationOf CYP24, which prevents its own local accumulation, however, mammary cells may be more susceptible to this than colonocytes.

Autocrine Metabolism of Vitamin D in Normal and Malignant Breast Tissue

The data indicate that the vitamin D–activating enzyme 1α-hydroxylase is up-regulated in breast tumors, and the enzymes involved in autocrine metabolism of vitamin D in breast tissue may provide important targets for both the prevention and treatment of breast cancer.

Vitamin D(3) receptor ablation alters mammary gland morphogenesis.

The results indicate that mammary glands from virgin Vdr knockout mice are heavier and exhibit enhanced growth, as evidenced by higher numbers of terminal end buds, greater ductal outgrowth and enhanced secondary branch points, compared with glands from age- and weight-matched wild-type mice.

Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer.

expression of VDR and the main enzymes involved in the synthesis and metabolism of calcitriol in gynecological malignancies and corresponding normal tissue are analyzed to indicate that cervical carcinomas, breast cancer and ovarian cancer may be considered as potential targets for prevention or therapy with new vitamin D analogs that exert little or no calcemic side effects.

Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.

1alpha(OH)D5 is a good candidate for in vivo chemoprevention studies and is nontoxic at a wide range of concentrations, but it is potent in inhibiting the development of preneoplastic lesions in mammary glands in organ culture experiments.

Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells.

These studies are the first to demonstrate that mammary-derived cells express megalin and cubilin, which contribute to the endocytic uptake of 25(OH)D3-DBP and activation of the VDR pathway.

25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture

25(OH)D3 could serve as a non-toxic natural chemopreventive agent for further development for breast cancer prevention and inhibits DMBA-induced mammary alveolar lesions (MAL) in a stage-specific manner.